[go: up one dir, main page]

BRPI0508895A - formas polimorficas e amorfa de {2-flúor-5-[3-((e)-2-piridn-2-il-vinil)-1h-indazol-6-ilamin]- fenil}-amida de ácido 2,5-dimetil-2h-pirazol-3-carboxìlico - Google Patents

formas polimorficas e amorfa de {2-flúor-5-[3-((e)-2-piridn-2-il-vinil)-1h-indazol-6-ilamin]- fenil}-amida de ácido 2,5-dimetil-2h-pirazol-3-carboxìlico

Info

Publication number
BRPI0508895A
BRPI0508895A BRPI0508895-0A BRPI0508895A BRPI0508895A BR PI0508895 A BRPI0508895 A BR PI0508895A BR PI0508895 A BRPI0508895 A BR PI0508895A BR PI0508895 A BRPI0508895 A BR PI0508895A
Authority
BR
Brazil
Prior art keywords
indazol
phenyl
vinyl
pyridn
pyrazol
Prior art date
Application number
BRPI0508895-0A
Other languages
English (en)
Inventor
Qiang Ye
Scott Edward Zook
Michael Allen Quellette
Donald Nicholas Hettinger
Jayaram Kasturi Srirangam
Robert Steven Kania
Nabil Lauze Saeed
Matthew David Wightlin
Mark Bryan Mitchell
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0508895A publication Critical patent/BRPI0508895A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

FORMAS POLIMORFICAS E AMORFA DE {2-FLúOR-5-¢3-((E)-2-PIRIDN-2-IL-VINIL)-1 H-INDAZOL-6-LAMIN!-FENIL}-AMIDA DE áCIDO 2,5-DIMETIL-2H-PIRAZOL-3-CARBOXiLICO. A invenção provê várias formas polimárficas e uma forma amorfa de {2-flúor-5-¢3-((E)-2-piridin-2-iI-viniI)-1 H-indazol-6-ilamino!-fenil}-amida de ácido 2,5-dimetil-2H-pirazol-3-carboxílico, composições farmacêuticas contendo tais formas poumórficas e amorfas, e métodos de uso de tais composições farmacêuticas para tratamento de estados de doenças mediados por prote¢nas cinases, tais como câncer e outros estados de doenças associados com indesejada angiogênese e/ou proliferação celular.
BRPI0508895-0A 2004-03-17 2005-03-04 formas polimorficas e amorfa de {2-flúor-5-[3-((e)-2-piridn-2-il-vinil)-1h-indazol-6-ilamin]- fenil}-amida de ácido 2,5-dimetil-2h-pirazol-3-carboxìlico BRPI0508895A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55414004P 2004-03-17 2004-03-17
PCT/IB2005/000616 WO2005090331A1 (en) 2004-03-17 2005-03-04 Polymorphic and amorphous forms of 2,5-dimethyl-2h-pyrazole-3-carboxylic acid {2-fluoro-5-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indasol-6-ylamino]-phenyl}-amide

Publications (1)

Publication Number Publication Date
BRPI0508895A true BRPI0508895A (pt) 2007-09-11

Family

ID=34961166

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508895-0A BRPI0508895A (pt) 2004-03-17 2005-03-04 formas polimorficas e amorfa de {2-flúor-5-[3-((e)-2-piridn-2-il-vinil)-1h-indazol-6-ilamin]- fenil}-amida de ácido 2,5-dimetil-2h-pirazol-3-carboxìlico

Country Status (16)

Country Link
US (1) US20050267158A1 (pt)
EP (1) EP1745035A1 (pt)
JP (1) JP2007529500A (pt)
KR (1) KR100816960B1 (pt)
CN (1) CN1930148A (pt)
AR (1) AR048268A1 (pt)
AU (1) AU2005223486A1 (pt)
BR (1) BRPI0508895A (pt)
CA (1) CA2559639A1 (pt)
CO (1) CO5721003A2 (pt)
IL (1) IL177434A0 (pt)
NO (1) NO20064675L (pt)
RU (1) RU2324692C1 (pt)
TW (1) TW200600511A (pt)
WO (1) WO2005090331A1 (pt)
ZA (1) ZA200606719B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006043172A1 (en) * 2004-10-19 2006-04-27 Pfizer Inc. Pharmaceutical compositions and methods for sub-tenon delivery
US20090111997A1 (en) * 2005-11-23 2009-04-30 Aaron Cote Method of Generating Amorphous Solid for Water-Insoluble Pharmaceuticals
JO3062B1 (ar) * 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
WO2017218365A1 (en) * 2016-06-16 2017-12-21 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK288365B6 (sk) * 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases

Also Published As

Publication number Publication date
JP2007529500A (ja) 2007-10-25
IL177434A0 (en) 2006-12-10
EP1745035A1 (en) 2007-01-24
AR048268A1 (es) 2006-04-12
KR100816960B1 (ko) 2008-03-25
WO2005090331A1 (en) 2005-09-29
AU2005223486A1 (en) 2005-09-29
US20050267158A1 (en) 2005-12-01
NO20064675L (no) 2006-11-28
CN1930148A (zh) 2007-03-14
CA2559639A1 (en) 2005-09-29
KR20060124769A (ko) 2006-12-05
TW200600511A (en) 2006-01-01
RU2324692C1 (ru) 2008-05-20
ZA200606719B (en) 2007-12-27
CO5721003A2 (es) 2007-01-31

Similar Documents

Publication Publication Date Title
BRPI0513477A (pt) composições e processos de uso de proteìna 4 semelhante a angiotensina
BR112012006252A2 (pt) "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
IL190796A (en) Composition containing nucleic acid encoded by anti-osteoclastogenic protein
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
BRPI0607988A2 (pt) composto, composição farmacêutica, e método para induzir apoptose em uma célula
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA201100158A1 (ru) Антагонисты активина-actriia и их применение для стимулирования роста кости
BRPI0717219A2 (pt) "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
WO2007007173A3 (en) Human anti-madcam antibodies
CL2008001122A1 (es) Compuestos derivados de imidazo[1,2,3-ij]-1,8-naftiridin-4,9-diona; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de infecciones bacterianas.
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
BRPI0514537B8 (pt) compostos de aminoeteroarila substituídos com pirazol e composição farmacêutica que os compreende
BRPI0714844B8 (pt) molécula de ácido nucleico e seus usos, composição farmaceutica e complexo
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
BRPI0411485A (pt) peptìdeo derivado de rasgap para matar seletivamente células cancerosas
CR9568A (es) DERIVADOS DE PIRIDO[2,3-d]PIRIMIDINA, SU PREPARACION, SU APLICACION EN TERAPEUTICA
ATE549353T1 (de) Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
EP2083018A3 (en) Compositions and methods relating to STOP-1
CL2004000677A1 (es) Compuestos derivados de piperidinas; procedimiento de preparacion; composicion farmaceutica; utiles como moduladores de la actividad del receptor de quimioquina en el tratamiento de enfermedades autoinmunes, inflamatorias, proliferativas o mediadas i
ATE487721T1 (de) Triaza-benzoäeüazulenderivate zur behandlung von tumoren
BRPI0508895A (pt) formas polimorficas e amorfa de {2-flúor-5-[3-((e)-2-piridn-2-il-vinil)-1h-indazol-6-ilamin]- fenil}-amida de ácido 2,5-dimetil-2h-pirazol-3-carboxìlico
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
DE60312684D1 (de) Plazenta-wachstumsfaktor als target für die behandlung von osteoporose

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.